Kodiak Sciences Inc.
KOD
Rankning i aktier
#3089
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Aktiekurs
$93.69
Senast synkroniserad: 2026-10-20
Marknadsvärde
$5.89B
Förändring (1 dag)
2.56%
Förändring (1 år)
393.11%
Land
US
Handel Kodiak Sciences Inc. (KOD)
Kategori
Healthcare
P/B-tal för Kodiak Sciences Inc. (KOD)
P/B-tal per October 2026 TTM: 83.12
Enligt Kodiak Sciences Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 83.12. I slutet av 2023 hade företaget ett P/B-tal på 0.60.
Historik för P/B-tal för Kodiak Sciences Inc. från 2016 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 83.12 | 2,288.62% |
| 2024 | 3.48 | 480.70% |
| 2023 | 0.60 | -30.10% |
| 2022 | 0.86 | -35.23% |
| 2021 | 1.32 | -15.19% |
| 2020 | 1.56 | -1.01% |
| 2019 | 1.58 | 168.87% |
| 2018 | 0.59 | -174.79% |
| 2017 | -0.78 | 113.24% |
| 2016 | -0.37 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -92.48% |
US
|
|
| 13.2547 | -84.05% |
US
|
|
| 4.208 | -94.94% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -92.56% |
NL
|
